Research

Early changes of CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis

Evangelos J Giamarellos-Bourboulis, Thomas Tsaganos, Ekaterini Spyridaki, Maria Mouktaroudi, Diamantis Plachouras, Ilia Vaki, Vassiliki Karagianni, Anastasia Antonopoulou, Vassiliki Veloni and Helen Giamarellou

4th Department of Internal Medicine, University of Athens, Medical School, 1 Rimini Str., Athens 124 62, Greece

Corresponding author: Evangelos J Giamarellos-Bourboulis, giamarel@ath.forthnet.gr

Received: 2 Sep 2006  Revisions requested: 29 Sep 2006  Revisions received: 21 Oct 2006  Accepted: 27 Nov 2006  Published: 27 Nov 2006

Critical Care 2006, 10:R166 (doi:10.1186/cc5111)

This article is online at: http://ccforum.com/content/10/6/R166

© 2006 Giamarellos-Bourboulis et al.; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction  Our aim was to define early changes in lymphocytes and of NK cells in severe sepsis and to correlate them with serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1).

Methods  Blood was sampled from 49 patients with proven highly suspected infection by Gram-negative pathogens, within 12 hours of the advent of severe sepsis, and was also sampled from six healthy volunteers. White blood cells were targeted with monoclonal antibodies and were analyzed by flow cytometry. The concentrations of sTREM-1 were estimated by ELISA.

Results  The presence of CD3/CD4 cells was significantly lower (P < 0.0001) and that of NK cells significantly higher among patients with sepsis compared with controls (P = 0.011). The proportions (median ± standard error) of ANNEXIN-V/CD4/CD3-positive cells, of ANNEXIN-V/CD8/CD3-positive cells and of ANNEXIN-V/CD14-positive cells of the patient population were 7.41 ± 2.26%, 7.69 ± 3.42% and 1.96 ± 4.22%, respectively. Patients with NK cells >20% survived longer compared with those patients with NK cells ≤20% (P = 0.041), and patients with sTREM-1 concentrations >180 pg/ml survived longer compared with those patients with sTREM-1 concentrations ≤180 pg/ml (P = 0.042). A negative correlation was found between the percentages of ANNEXIN-V/CD4/CD3-positive cells and of CD3/CD4 cells (r = -0.305, P = 0.049), and a positive correlation was found between the serum sTREM-1 concentration and the percentage of NK cells (r = +0.395, P = 0.014). NK cells isolated from two healthy volunteers released sTREM-1 upon triggering with endotoxins.

Conclusion  Early severe sepsis is characterized by CD4-lymphopenia and increased NK cells, providing a survival benefit for the septic patient at percentages >20%. The survival benefit resulting from elevated NK cells might be connected to elevated serum levels of sTREM-1.

Introduction

Human studies in patients with sepsis have shown considerable changes in the subpopulations of lymphocytes [1], and particularly of those lymphocytes participating in adaptive immunity. These changes involve decreases of T-helper cells and of B lymphocytes. Data about the exact time point in the septic cascade where these changes occur are not available, however, although these data are of extreme importance since depletion of lymphocytes renders the septic hosts susceptible to further infectious insults.

Sparse data of either animal or human studies implicate a crucial role of new counterparts of the innate immune system in the pathogenesis of sepsis. These data comprise NK cells that are a subpopulation of lymphocytes behaving as cells of the innate immune system [2], as well as neutrophils and monocytes expressing the triggering receptor expressed on myeloid cells-1 receptor on their cell membranes in the event of human sepsis [3]. The soluble form of this receptor, namely soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), is proposed to act as an anti-inflammatory mediator and to contribute to the transition from sepsis to septic shock [4,5].
Based on the latter evidence, the present study investigated whether changes of lymphocytes and NK cells occur early in severe sepsis. A cohort of patients with severe sepsis due to proven or highly suspected infection by Gram-negative bacteria was utilized. The use of this cohort stemmed from the necessity to study a population as homogeneous as possible for the type of antigenic stimulus. Changes of subpopulations of lymphocytes and of NK cells were also correlated to serum levels of sTREM-1.

Patients and methods
Study design
All patients hospitalized in the 4th Department of Internal Medicine of the 'ATTIKON' University Hospital of Athens during the period November 2004 to January 2006 were delegates for the study. The protocol was approved by the Ethics Committee of the hospital and written informed consent was provided by the patients or their relatives.

Inclusion criteria were the concomitant presence of acute pyelonephritis, acute intra-abdominal infection or nosocomial pneumonia within the past 36 hours, and signs of severe sepsis within the past 12 hours. Exclusion criteria were neutropenia within the past 36 hours, and signs of severe sepsis. A cohort of patients with severe sepsis due to proven or highly suspected infection by Gram-negative bacteria was utilized. The use of this cohort stemmed from the necessity to study a population as homogeneous as possible for the type of antigenic stimulus. Changes of subpopulations of lymphocytes and of NK cells were also correlated to serum levels of sTREM-1.

Severe sepsis was determined as the acute dysfunction of at least one organ, indicated by the acute presentation of at least one of the following [9]: acute respiratory distress syndrome, defined as any pO2/FiO2 <200; acute renal failure, defined as the production of <0.5 ml urine/kg body weight per hour for at least two hours provided that the negative fluid balance of the patient was corrected; metabolic acidosis, defined as any pH <7.30 or any base deficit >5 mEq/l and serum lactate at least more than twice the normal value; acute coagulopathy, defined as any platelet count <100,000/μl or an International Normalized Ratio (INR) >1.5; and acute cardiovascular failure, defined as systolic pressure <90 mmHg requiring the administration of inotropic agents for more than one hour provided the negative fluid balance of the patient was corrected.

Fifty-three patients were eligible for the study; four of these patients denied informed consent. A total of 49 patients were therefore enrolled.

Upon enrolment in the study, 10 ml blood was collected. Five milliliters were added to flasks for culture, another 3 ml were collected in an ethylenediamine tetraacetic acid-coated tube (Becton Dickinson, Cockeysville, MD, USA) for immunophenotyping, and the remaining blood was added in a sterile tube. After centrifugation, the serum was kept at -70°C until assayed. Flasks with blood were incubated for seven days. Identification of pathogens was performed by the API20E and the API20NE systems (bioMérieux, Paris, France). Enrolled patients were followed-up on a daily basis for a total of 28 days.

Laboratory techniques
Red blood cells were lysed with ammonium chloride 1.0 mM in the whole-blood sample collected into ethylenediamine tetraacetic acid-coated tubes. White blood cells were washed three times with PBS (pH 7.2) (Merck, Darmstadt, Germany); the cells were subsequently incubated for 15 minutes in the dark with the monoclonal antibodies anti-CD3 and anti-CD19 and the protein ANNEXIN-V with the fluorochrome fluorescein isothiocyanate (emission 520 nm; Immunotech, Marseille, France), and with the monoclonal antibodies anti-CD4, anti-CD8, anti-CD14 and anti-CD16+56 with the fluorochrome phycoerythrin (emission 550 nm; Immunotech) with or without the monoclonal antibody anti-CD3 with fluorochrome PC5 (emission 600 nm; Immunotech).

The following combinations were applied: anti-CD3/anti-CD4, anti-CD3/anti-CD8, anti-CD3/anti-CD (16+56), ANNEXIN-V/anti-CD4/anti-CD3, ANNEXIN-V/anti-CD8/anti-CD3 and
ANNEXIN-V/antiCD14. Anti-CD19 was applied singularly. Cells staining positive for the above antibodies were analyzed after running through the EPICS XL/MSL flow cytometer (Beckman Coulter Co., Miami, FL, USA) with gating for lymphocytes or monocytes based on their characteristic FS/SS scattering. NK cells were defined as CD3-negative and CD(16+56)-positive cells.

Blood was also sampled from six healthy volunteers equally matched for age with the study population. IgG isotypic-negative controls with the fluorocolors fluorescein isothiocyanate and phycoerythrin (Immunotech) were applied before the start of analysis for each patient.

Estimation of sTREM-1 was performed by a home-made enzyme immunoassay. The capture antibody of sTREM-1 (R&D Inc., Minneapolis, MN, USA) was diluted to 4,000 ng/ml and distributed in a 96-well plate at a volume of 0.1 ml/well. After overnight incubation at 25°C, the wells were thoroughly washed with a 0.05% solution of Tween in PBS (Merck) (pH 7.2–7.4). Then 0.1 ml standard concentrations of sTREM-1 (15.1–4,000 pg/ml; R&D Inc.) or serum was added to the wells. After incubation for two hours, the wells were washed three times and 0.1 ml of one 400 ng/ml dilution of sTREM-1 detection antibody (R&D Inc.) was added per well. The plate was then incubated for two hours, and attached antibodies were signaled by streptavidin horse radish peroxidase. The concentrations of sTREM-1 in each well were estimated by the optical density detected at 450 nm after addition of one 1:1 solution of H₂O₂: tetramethylbenzidine as a substrate (R&D Inc.). All determinations were performed in duplicate; the inter-day variation of the assay was 5.23%.

Isolation of NK cells

NK cells were isolated from two healthy volunteers, as already described [10]. Briefly, heparinized venous blood was layered over Ficoll Hypaque (Biochrom, Berlin, Germany) and was centrifuged. Theuffy coat was washed three times with PBS (pH 7.2) (Merck), and was then diluted at a volume of 2 ml in RPMI 1640 (Biochrom) and incubated with 0.2 ml RosetteSep NK antibody cocktail (StemCell Technologies, Seattle, WA, USA) for one hour at room temperature with thorough mixing every ten minutes. The buffy coats were layered over Ficoll Hypaque and were centrifuged for 20 minutes at 1,200 x g. After centrifugation, any cells remaining over Ficoll Hypaque were collected and washed three times in PBS (pH 7.2). These cells were then stained with anti-CD3 fluorescein isothiocyanate and anti-CD(16+56) phycoerythrin, and were analyzed after running through the EPICS XL/MSL flow cytometer with the application of cells stained with IgG isotypic antibodies as negative controls. The collected cells were CD(16+56)-positive and CD3-negative at a purity greater than 90%.

NK cells were distributed into two wells of a 12-well plate with 2.4 ml RPMI 1640 enriched with 10% fetal bovine serum (Biochrom). Lipopolysaccharide of Escherichia coli O111: B4 (Sigma, St Louis, MO, USA) was added to the second well at a concentration of 10 ng/ml. The experiment was run in duplicate for each volunteer. After incubation for 18 hours at 37°C in 5% CO₂, the content of each well was collected and centrifuged. sTREM-1 was estimated in the supernatants, as described above.

Statistical analysis

Results are expressed as the median and interquartile range, but those of cell cultures expressed as the means and standard deviation. Comparisons between patients and healthy controls were performed by the Mann–Whitney U test. Statistical correlations were performed after assessment of the nonparametric Spearman coefficient (rₛ).

The time of survival was estimated after Kaplan-Meier analysis; patients were divided into two groups based on serum levels of sTREM-1 and on the percentage of NK cells. The patients were categorized into those with serum sTREM-1 ≤180 pg/ml and serum sTREM-1 >180 pg/ml, as proposed elsewhere [11]. After scattering of individual values of NK cells for survivors and nonsurvivors, the patients were also divided into those with NK ≤20% and NK >20%. Comparisons between these subgroups for survival were performed by log-rank tests.

Comparisons of qualitative data were performed according to Fischer’s test. P < 0.05 was considered statistically significant.

Results

Clinical characteristics of the patients enrolled in the study are presented in Table 1. Subpopulations of lymphocytes of patients compared with healthy controls are presented in Table 2. CD3/CD4 cells were significantly lower in early severe sepsis patients compared with controls (P < 0.0001). NK cells were significantly higher in early severe sepsis patients compared with controls (P = 0.011).

The median percentage of ANNEXIN-V/CD4/CD3-positive cells was 7.41%, with a 25th percentile of 1.70% and a 75th percentile of 19.81%. The median percentage of ANNEXIN-V/CD8/CD3-positive cells was 7.69%, with a 25th percentile of 2.13% and a 75th percentile of 17.00%. The median percentage of ANNEXIN-V/CD14-positive cells was 1.96, with a 25th percentile of 0.00% and a 75th percentile of 6.54%.

The survival curves of patients in relation to the percentage of NK cells are shown in Figure 1. Patients with NK cells >20% survived longer compared with those patients with NK cells ≤20% (P = 0.041). Twenty-four out of 38 patients with NK cells >20% died (63.2%), compared with three out of 11 patients with NK cells >20% (27.3%, P = 0.046).
Table 1

Clinical characteristics of 49 patients with early severe sepsis enrolled in the study

| Characteristic                          | Severe sepsis          |
|----------------------------------------|------------------------|
| Age (years)                            | 77.0 ± 11.9            |
| Male/female                            | 28/21                  |
| Acute Pathophysiology and Chronic Health Evaluation II score | 20.2 ± 9.1            |
| Sequential Organ Failure Assessment score | 8.53 ± 3.35          |
| Underlying infection                   |                        |
| Acute pyelonephritis                   | 29 (59.2)              |
| Acute intra-abdominal infection         | 12 (24.5)              |
| Nosocomial pneumonia                   | 9 (18.4)               |
| Bacterial pathogen                     |                        |
| *Escherichia coli*                     | 10 (20.4)              |
| *Klebsiella pneumoniae*                | 3 (6.1)                |
| *Acinetobacter baumannii*              | 3 (6.1)                |
| *Morganella morganii*                  | 2 (4.1)                |
| Others                                 | 2 (4.1)                |
| Bacteremia                             | 9 (18.4)               |
| Case fatality                          | 27 (55.1)              |

Data presented as the mean ± standard deviation or as n (%).

Table 2

Subpopulations of lymphocytes of 49 patients with early severe sepsis and six healthy controls

|                     | Median  | 5th percentile | 25th percentile | 75th percentile | 95th percentile | P value |
|---------------------|---------|----------------|-----------------|-----------------|-----------------|---------|
| CD3/CD4 lymphocytes (%) |         |                |                 |                 |                 |         |
| Controls            | 45.83   | 39.40          | 42.24           | 53.74           | -               | <0.0001 |
| Severe sepsis       | 24.71   | 2.85           | 13.97           | 30.27           | 44.76           |         |
| CD3/CD8 lymphocytes (%) |         |                |                 |                 |                 |         |
| Controls            | 24.87   | 14.92          | 19.89           | 28.09           | -               | NS      |
| Severe sepsis       | 20.93   | 3.09           | 13.00           | 30.53           | 51.39           |         |
| CD3/CD16+56 lymphocytes (%) |      |                |                 |                 |                 |         |
| Controls            | 4.50    | 1.77           | 1.91            | 7.43            | -               | NS      |
| Severe sepsis       | 6.10    | 0.76           | 3.03            | 10.75           | 24.75           |         |
| CD19 lymphocytes (%) |         |                |                 |                 |                 |         |
| Controls            | 8.74    | 7.76           | 7.81            | 11.62           | -               | NS      |
| Severe sepsis       | 4.70    | 0.48           | 2.51            | 10.09           | 22.77           |         |
| CD3(-)/CD16+56 lymphocytes (NK cells) (%) |     |                |                 |                 |                 |         |
| Controls            | 4.12    | 0.25           | 1.26            | 8.94            | -               | 0.011   |
| Severe sepsis       | 11.32   | 2.25           | 7.05            | 18.25           | 33.69           |         |

NS, not significant.
The survival curves of patients in relation to serum sTREM-1 levels are shown in Figure 2. Patients with sTREM-1 > 180 pg/ml survived longer compared with those patients with sTREM-1 ≤ 180 pg/ml ($P = 0.042$). Twenty-two out of 33 patients with sTREM-1 ≤ 180 pg/ml died (66.7%), compared with five out of 16 patients with sTREM-1 > 180 pg/ml (31.3%, $P = 0.032$).

A negative correlation was found between the percentages of ANNEXIN-V/CD4/CD3-positive cells and of CD3/CD4 cells ($r_s = -0.305$, $P = 0.049$). A positive correlation was also found between serum sTREM-1 and the percentage of NK cells ($r_s = +0.395$, $P = 0.014$).

The concentrations of sTREM-1 released by NK cells of healthy volunteers and their modification after triggering by lipopolysaccharide are shown in Figure 3.

**Discussion**

The identification of early changes taking place in the clinical setting of a septic host is of prime importance in order to understand the underlying pathogenesis. The majority of clinical studies do not provide evidence about the alterations of the immune responses within a short time frame after occurrence of organ failure. The lack of knowledge of early changes responsible for the transition from one stage of sepsis to another has been proposed as one reason responsible for the failure of numerous trials of immunointervention in sepsis [12].

The present study was designed to provide information about the early changes of adaptive immune responses and of NK cells occurring within the first 12 hours after advent of severe sepsis. Moreover, the entire population became septic because of the same antigenic stimulus – one Gram-negative pathogen. This was achieved by enrolling patients with infec-
tions clinically thought to be caused by Gram-negative bacteria or having been proved with a microbiological documentati
on of their infection being solely of Gram-negative origin (Table 1). The need for enrolment of patients with Gram-nega

tive severe infections derived from the high frequency of Gram-negative bacteria as pathogens [13]. Findings of the
study were correlated to serum levels of sTREM-1, which is a novel anti-inflammatory mediator of prime importance for
the transition from severe sepsis to septic shock [4,5].

The results revealed two major early changes in the subpopu
lations of mononuclear cells of the study population. The first
finding consists of a considerable decrease of CD3/CD4 lym
phocytes (Figure 1). This depletion of CD4-positive lym
phocytes resulted from cell apoptosis since the percentage of
total CD3/CD4 cells was negatively correlated to the per
centage of apoptotic CD3/CD4 cells. CD4-lymphopenia

as a consequence of apoptosis is a well-described finding in
septic patients [1,13-15]. The presented median rate of apop
tosis of 7.41% CD4-positive cells is within the range reported
elsewhere for septic patients [16]. The present study is the
first to report the very early occurrence of CD4-lymphopenia
in severe sepsis. The applied flow cytometric analysis of apo
ptosis did not use propidium iodine staining positive for necrotic
cells. Application of the analysis was difficult due to the appli
cation of a triple combination of fluorocolors for apoptotic lym
phocytes, rendering possible the yield of false-positive results
for propidium iodine staining. The reported negative correla
tion between CD3/CD4 cells and the percentage of ANNEXIN-V/CD4/CD3 cells allows one, with safety, to trust
the analysis of apoptosis.

Contrary to CD4-positive T lymphocytes, B lymphocytes (that
is, CD19-positive cells) remained unaltered (Figure 2). This
finding probably suggests that B-lymphopenia, described by
others [15], is a phenomenon supervening later in the series of
events of sepsis.

The second major early change in the study population was an
increase of NK cells (Table 2) directly connected to the out
come of the patients in such a manner that a percentage of NK
cells >20% was connected to survival benefit, as opposed to
patients with NK cells ≤20% (Figure 1). In a former study by
Hotchkiss and colleagues [15], focused on immunophenotyp
ing of cells of the spleen taken from septic patients postmor
tem or late after the advent of sepsis, an increase of NK cells
was described; however, the increase failed to reach statisti
cal significance compared with controls. Our study is the first
statistically confirming an early increase of NK cells in severe
sepsis. Animal studies of experimental infections by strep
tococci concluded that triggering of NK cells was accompanied
by rapid progression to death [17,18]. The latter experimental
findings are opposite to the beneficiary effect of NK cells
reported in the present study. A probable explanation might be
that in the present cohort of patients severe sepsis was of
Gram-negative origin, whereas pathogens were Gram-positive
cocci in former animal studies.

An explanation for the protective effect of increased NK cells
for the septic host may be provided by the positive correlation
between the percentage of NK cells and serum sTREM-1 con
centrations. sTREM-1 is a novel mediator considered to play
an anti-inflammatory role in sepsis [5]. The present study is in
accordance with previous results by other authors connecting
serum levels of sTREM-1 >180 pg/ml with prolonged survival of
the septic host [11] (Figure 2). NK cells have never been
reported to be a reservoir for the production of sTREM-1. In
vitro results with cells of healthy volunteers revealed the
potency of NK cells for the production of sTREM-1 upon trig
gering with lipopolysaccharide (Figure 3). Moreover, the trig
gering receptor expressed on myeloid cells-1 has a functional
homology to the NKP44 receptor expressed on cell mem
branes of NK cells [19]. If NK cells of the septic hosts are a
source for sTREM-1, then their protective role in early severe
sepsis may be explained.

Conclusion

The present study provided evidence for the first time that
early severe sepsis is characterized by CD4-lymphopenia and
an increased presence of NK cells, providing a survival benefit
for the septic patient at percentages >20%. The survival ben
efit resulting from elevated NK cells may be connected to ele
vated serum levels of sTREM-1.

Key messages

- Early severe sepsis is characterized by CD4-lymphoto
nia and an increased presence of NK cells.

- Percentages of NK cells in early severe sepsis >20%
and concentrations of sTREM-1 in serum >180 pg/ml
are accompanied by prolonged survival.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

EJG-B participated in the study design, coordinated the lab
job, analyzed the data and wrote the manuscript. TT partici
pated in the study design and the estimation of sTREM-1. ES
and VK participated in the immunophenotypic analysis. MM
participated in the follow-up of patients. DP participated in the
enrolment of patients. IV, AA and VV participated in the follow
up of patients. HG drafted the manuscript.

References

1. Holub M, Kluèkova Z, Beneda B, Hobstová J, Hužíčka I, Pražák J,
Lobovská A: Changes in lymphocyte subpopulations and
CD3/DR expression in sepsis. Clin Microbiol Infect 2000,
6:657-660.

2. Emoto M, Miyamoto M, Yoshizawa I, Emoto Y, Schaeibe UE, Kita E,
Kaufmann SHE: Critical role of NK cells rather than Vα14+NKT
cells in lipopolysaccharide-induced lethal shock in mice. J Immunol 2002, 169:1426-1432.

3. Bouchon A, Facchetti F, Welgand MA, Colonna M: TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001, 410:1103-1107.

4. Routsi C, Giamarellos-Bourboulis EJ, Antonopoulou A, Kollias S, Siafakas N, Kononias A, Zakynthinos S, Armaganidis A, Giamarellos Bouriou MC, Roussos A: Does soluble triggering receptor expressed on myeloid cells-1 play any role in the pathogenesis of septic shock? Clin Exp Immunol 2005, 142:62-67.

5. Giamarellos-Bourboulis EJ, Zakynthinos S, Baziak F, Papa-domichelakis E, Virtzili S, Koutoukas P, Armaganidis A, Giamarellos Bouriou MC, Roussos C: Soluble triggering receptor expressed on myeloid cells-1 as an anti-inflammatory mediator in sepsis. Intensive Care Med 2006, 32:237-243.

6. Pinson AG, Philbrick JT, Lindbeck GH, Schorling JB: Fever in the clinical diagnosis of acute pyelonephritis. Am J Emerg Med 1997, 15:148-151.

7. Calandra T, Cohen J, International Sepsis Forum Definition of Infection in the ICU Consensus Conference: The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 2005, 33:1538-1548.

8. Baughman RP: Diagnosis of ventilator-associated pneumonia. Curr Opin Crit Care 2003, 9:397-402.

9. Levy M, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003, 31:1250-1256.

10. Whalen MM, Green SA, Loganathan BG: Brief butyltin exposure induces irreversible inhibition of the cytotoxic function on human natural killer cells, in vitro. Environ Res 2002, 88:19-29.

11. Gibot S, Cravoisy A, Kolopp-Sarda MN, Béné MC, Faure G, Bollaert PE: Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med 2005, 33:792-796.

12. Vincent JL, Sun Q, Dubois MJ: Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002, 34:1084-1093.

13. Annane D, Aegerter P, Jars-Guincestre MC, Giudet B: Current epidemiology of septic shock. The CUB-Réa network. Am J Resp Crit Care Med 2003, 168:165-172.

14. Hotchkiss RS, Osmon SB, Chang KC, Wagner TH, Coopersmith CM, Karl IE: Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol 2005, 174:5110-5118.

15. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr, Hui JJ, Chang KC, Osborne DF, Freeman BD, Cobb JP, Buchman TG, et al.: Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001, 166:6952-6963.

16. Le Tulzo Y, Pangault C, Gacoulin A, Guilloux V, Tribot O, Amiot L, Tattevin P, Thomas R, Fauchet R, Drenou B: Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 2002, 18:487-494.

17. Kerr AR, Kirkham LAS, Kadioglu A, Andrew PW, Gasaside P, Thompson H, Mitchell TJ: Identification of a detrimental role for NK cells in pneumococcal pneumonia and sepsis in immunocompromised hosts. Microbes Infect 2005, 7:845-852.

18. Goldmann O, Chhatwal GS, Medina E: Contribution of natural killer cells to the pathogenesis of septic shock induced by Streptococcus pyogenes in mice. J Infect Dis 2005, 191:1280-1286.

19. Colonna M, Facchetti F: TREM-1 (triggering receptor expressed on myeloid cells): a new player in acute inflammatory responses. J Infect Dis 2003, 187(Suppl 2):S397-S401.